80wk Uptrend — rising+above (sma 46.63 vs px 88.88)
200wk Uptrend — rising+above (sma 35.48 vs px 88.88)
Funds Accumulating — momZ +3.27 · 4.87→5.65
Short Squeeze Setup — velZ +2.38 · age 68w×0.56 · 7.89%
Founder-Led — founder/CEO led
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clini… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: June 16, 1993
Headquarters: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
Founder-Led: Yes — Christopher Anzalone (President, CEO and Chairman of the Board)
Key Metrics
Current Price
$88.88
Market Cap
$12.36B
Float
122.5M
Shares Outstanding
141.3M
P/E (Forward)
111.11
Price/Sales (TTM)
18.46
vs. Analyst Target
+24.0% to analyst PT
Profit Margin
-47.79%
Operating Margin (TTM)
-226.03%
Revenue (TTM)
$669M
Earnings Growth (YoY)
9.80%
Dividend Rate
None
Analyst Target Price
$110.18 (13 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$88.0M
-$84.6M
$88.0M
-$87.2M
2021
$138M
-$141M
$138M
-$133M
2022
$243M
-$176M
$243M
-$168M
2023
$241M
-$205M
$228M
-$176M
2024
$3.6M
-$599M
-$15.0M
-$562M
2025
$829M
-$1.6M
$829M
$165M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$256M
-$23.8M
Dec 2025
$264M
$30.8M
Mar 2026
$73.7M
-$133M
Jun 2026
$75.3M
-$194M
Ownership & Float
Insider Ownership
3.7%
Institutional Ownership
85.6%
Short Float
7.9%
% of All Funds Holding
5.65%
Number of Funds Holding
497
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$83.41
Near-term / short-term trend
Weekly
40-Week SMA
$71.24
Medium-term trend
Weekly
80-Week SMA
$46.63
Cyclical trend (business cycle)
Weekly
200-Week SMA
$35.48
Secular trend (multi-year)
Monthly
10-Month SMA
$72.08
Near-term monthly trend
Monthly
20-Month SMA
$46.64
Medium-term monthly trend
Monthly
40-Month SMA
$36.71
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$53.00
support
1.29x
7 months ago
$42.00
support
1.14x
8 months ago
$22.80
support
1.46x
10 months ago
$15.50
support
1.30x
11 months ago
$13.90
support
1.15x
14 months ago
Historical Earnings Reactions (82 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.67%
0.00%
46.34%
30.19%
-8.48%
1 Day
0.20%
-0.28%
41.46%
24.23%
-26.85%
1 Week
1.92%
0.65%
52.44%
38.19%
-30.38%
2 Weeks
3.36%
0.24%
50.00%
51.36%
-50.63%
1 Month
6.82%
2.62%
54.32%
81.99%
-52.25%
Next earnings: October 23, 2026 (57 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
30.2%
51.5%
33
Feb
-6.2%
36.4%
33
Mar
9.6%
48.5%
33
Apr
6.6%
42.4%
33
May
1.4%
36.4%
33
Jun
0.1%
48.5%
33
Jul
1.6%
51.5%
33
Aug
4.2%
37.5%
32
Sep
8.0%
50.0%
32
Oct
-7.1%
34.4%
32
Nov
5.0%
46.9%
32
Dec
6.5%
40.6%
32
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.73%
32.4%
1547
Tuesday
0.04%
35.0%
1689
Wednesday
1.15%
37.1%
1687
Thursday
0.31%
33.7%
1655
Friday
1.10%
34.0%
1647
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 85.6%
Insider Transactions — Smart Summary
Total insider ownership: 3.7%
Founder-led management: Christopher Anzalone (President, CEO and Chairman of the Board)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Arrowhead Pharmaceuticals Inc
(ARWR) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.